Nicolò Scarsi

Nicolò Scarsi

Auto-generated profile, based on publicly available information

Nicolò Scarsi

University Department of Life Sciences and Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, Roma, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
APAngelo Maria Pezzullo
Angelo Maria Pezzullo
AGAngelica Valz Gris
Angelica Valz Gris
NSNicolò Scarsi
Nicolò Scarsi
DTDiego Maria Tona
Diego Maria Tona
MPMartina Porcelli
Martina Porcelli
SBStefania Boccia
Stefania Boccia
Genetic and genomic tests are the cornerstone of personalized preventive approaches. Inconsistency in evaluating their clinical utility is often cited as a reason for their limited implementation in clinical practice. Previous reviews have primarily focused on theoretical frameworks used for clinical utility evaluations of genetic tests, rather than actual assessments and examined dimensions, rather than specific indicators within these dimensions. We aimed to review the dimensions and the specific indicators measured in published assessment reports of genetic or genomic tests. We conducted a scoping review of assessment reports of genetic and genomic tests used for prevention, searching through PubMed, Web of Science, Scopus, the websites of 20 different organizations, Google, and Google Scholar. From the included assessments, we extracted the reported indicators of clinical utility, compiling a list of disease-specific indicators that detailed their numerator, denominator, and calculation methods. We analyzed the extracted indicators by stratifying them according to ten comprehensive dimensions of clinical utility, the assessment framework used, and the type of indicator (categorized as quantitative, qualitative, reference, or no evidence reported). From these indicators, we then distilled a list of general indicators. We reviewed 3054 unique references and 12,000 results from gray literature searches, ultimately selecting 57 assessment reports. The reference frameworks used were health technology assessment (HTA) (42%), Evaluation of Genomic Applications in Practice and Prevention (EGAPP) (25%), ACCE (21%), and others (12%). We identified 951 disease-specific indicators. The dimensions most frequently evaluated (ie, had at least one indicator) were analytic validity (60%), clinical validity (79%), clinical efficacy (79%), and economic impact (58%). Only 12 assessments compared health outcomes between tested and untested groups, and fewer than 15% of the assessments addressed equity, acceptability, legitimacy, and personal value. Our study illustrates that, although dimensions such as equity and acceptability, are significantly emphasized in traditional evaluation frameworks, these are often not considered in the assessments. Additionally, our study has underscored a significant dearth of reported primary evidence concerning the clinical efficacy of these tests. Genetic and genomic tests analyze a person's genes to predict health risks and guide healthcare decisions, potentially identifying who might benefit from certain treatments or check-ups. However, determining whether these tests are genuinely useful for wide use in health services is complex, because there is no standard way to define "clinical utility" of a genetic test. To understand how these tests are evaluated, we reviewed 57 evaluation reports from high-income countries, most of which focused on cancer-related genetic tests. We found that many evaluations looked mainly at how well a test predicted a condition (validity) and considered some form of effectiveness, yet often failed to measure whether the test truly improved patient health outcomes, such as lowering death rates or enhancing the quality of life. Moreover, factors like patient acceptance, equity, and personal relevance (eg, reducing anxiety) were frequently overlooked. Without including these broader considerations, evaluations risk missing critical evidence that would indicate whether a test is helpful, fair, and worth using. From over 900 unique indicators used to measure clinical utility, we created a simpler list of about 150 general indicators that can guide future evaluations. This consolidated list can help test developers decide which factors to investigate, evaluators determine what to measure, and policymakers identify what might be missing before deciding if a test should be adopted in healthcare. By highlighting the gaps-areas that should be assessed but currently are not-our study encourages a more comprehensive approach to evaluating genetic tests. If we fail to consider issues like equity, patient preferences, and proven health benefits, we risk investing in tests that may do little good or even harm patients. Ultimately, recognizing these shortcomings can lead to better-informed decisions, ensuring that genetic testing is used in ways that truly benefit patients and deliver safer, more personalized, and fairer healthcare for everyone.

27 April 2023 in Population Medicine
Verified
Journal Article
Open access
NSNicolò Scarsi
Nicolò Scarsi
APAngelo Maria Pezzullo
Angelo Maria Pezzullo
CSCosimo Savoia
Cosimo Savoia
RPRoberta Pastorino
Roberta Pastorino
GRGian Marco Raspolini
Gian Marco Raspolini
SBStefania Boccia
Stefania Boccia
A large body of literature showed the importance of dietary patterns (DPs) analysis in nutritional epidemiology. The objective of this research was to derive and characterize adults dietary patterns in a large Italian population-based cohort and to assess individuals’ diet adherence with...

23 January 2026 in UCL Open Environment
Verified
Journal Article
Open access
AMAlisha Morsella
Alisha Morsella
LCLota Alcantara Creencia
Lota Alcantara Creencia
RPRadisti Praptiwi
Radisti Praptiwi
NSNicolò Scarsi
Nicolò Scarsi
GLGaia Surya Lombardi
Gaia Surya Lombardi
MGMatthew O. Gribble
Matthew O. Gribble
Harmful algal blooms occurring in the marine environment cause a variety of human illnesses in Southeast Asians, who rely on the marine ecosystem for sustenance, yet there is limited public understanding of these disease risks. Due to a lack of awareness, diagnostic uncertainty, and fragmented surveillance, the burden of disease attributable to harmful algal blooms exposure remains unclear. This scoping review aimed to map surveillance and data collection mechanisms, and inter-organisational data flows concerning marine harmful algal bloom-related health outcomes in the Philippines, Malaysia and Indonesia. The review followed Arksey and O’Malley’s framework and the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews reporting guidelines, searching PubMed, Web of Science and Scopus (1970–2024) and complementary searches in Google Scholar. Data extraction focused on intoxication types, data sources, reporting mechanisms and stakeholder collaborations. Twenty-three studies and records were included: 70% from the Philippines, 26% from Malaysia and 4% from Indonesia. Five main surveillance data sources were identified: (i) physician reports, (ii) healthcare facility records, (iii) local health authorities, (iv) Department of Health systems and (v) document-based and media-based data sources. However, key data infrastructure was poorly documented. The Philippines demonstrated the most diversified data pathways, emphasising multi-stakeholder collaborations. This review reveals that the infrastructure for harmful algal bloom-related health surveillance across the countries is largely absent or undocumented. Strengthening data systems and enhancing multisectoral collaboration are essential to mitigate the health threats posed by harmful algal blooms.

21 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
NSNicolò Scarsi
Nicolò Scarsi
RPRoberta Pastorino
Roberta Pastorino
CSCosimo Savoia
Cosimo Savoia
GRGian Marco Raspolini
Gian Marco Raspolini
APAngelo Maria Pezzullo
Angelo Maria Pezzullo
SBStefania Boccia
Stefania Boccia
Background & objective.: Diet is among the most significant modifiable risk factors for reducing the global burden of chronic diseases. This study aims to investigate the dietary patterns of adults in a large representative sample of the Italian population and to analyze these patterns according to sociodemographic characteristics. Methods: Adult participants of the third Italian National Food Consumption Survey (INRAN- SCAI 2005-06) were included. A total of 878 food items were classified into 24 pre-defined food groups using the FoodEx2 classification system. Dietary patterns were identified through principal component analysis, and Z-scores were calculated to assess adherence to these patterns. Associations between sociodemographic characteristics, energy intake, and dietary adherence scores were investigated using linear regression models. Results: Based on data from 2,831 subjects (median age 47, IQR 35-60), five principal components (PCs) were retained, explaining 35.6% of the overall variance. PC1 was indicative of a high-fat diet, PC2 suggested a western eating behavior, PC3 represented a health-conscious lifestyle, PC4 can be characterized as an Italian traditional diet, and PC5 represented an unhealthy dietary pattern. According to Z-scores, 42.4% of our study cohort showed high adherence to at least one of the dietary patterns. Less healthy dietary patterns were more prevalent among males and individuals from northern Italian regions. Conclusions: Our results indicate a significant regional variation in terms of dietary pattern, mirroring the general trends of Italian eating habits of the last decades, characterized by a higher tendency towards a more westernized lifestyle. These findings underscore the importance of considering region-specific characteristics when designing future public health interventions and establishing national dietary guidelines.

4 November 2026 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
NLNicolò Lentini
Nicolò Lentini
FBFrancesca Bravi
Francesca Bravi
DLDoriana Lacalaprice
Doriana Lacalaprice
LPLINIA Patel
LINIA Patel
CPClaudio Pelucchi
Claudio Pelucchi
FTFederica Turati
Federica Turati